Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 2
1970 1
1972 1
1973 2
1974 1
1975 3
1976 6
1977 1
1978 2
1979 3
1980 3
1981 4
1982 4
1983 8
1984 5
1985 12
1986 19
1987 13
1988 7
1989 10
1990 22
1991 17
1992 27
1993 21
1994 29
1995 18
1996 26
1997 25
1998 19
1999 31
2000 35
2001 22
2002 31
2003 44
2004 38
2005 24
2006 45
2007 42
2008 48
2009 33
2010 26
2011 29
2012 22
2013 20
2014 25
2015 20
2016 17
2017 17
2018 12
2019 10
2020 10
2021 9
2022 16
2023 8
2024 13
2025 6
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

922 results

Results by year

Filters applied: . Clear all
Page 1
Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.
Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, Almendral J; PROCAMIO Study Investigators. Ortiz M, et al. Eur Heart J. 2017 May 1;38(17):1329-1335. doi: 10.1093/eurheartj/ehw230. Eur Heart J. 2017. PMID: 27354046 Free PMC article. Clinical Trial.
AIMS: Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. ...Tachycardia terminated within 40 min in 22 (67%) procainamide and 11 (38%) amioda …
AIMS: Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice bet …
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Flaker G, et al. J Am Coll Cardiol. 2014 Oct 14;64(15):1541-50. doi: 10.1016/j.jacc.2014.07.967. J Am Coll Cardiol. 2014. PMID: 25301455 Free article. Clinical Trial.
METHODS: Baseline characteristics of patients who received amiodarone at randomization were compared with those who did not receive amiodarone. The interaction between randomized treatment and amiodarone was tested using a Cox model, with main effects for ran …
METHODS: Baseline characteristics of patients who received amiodarone at randomization were compared with those who did not receive …
Intravenous amiodarone for ventricular arrhythmias: overview and clinical use.
Gonzalez ER, Kannewurf BS, Ornato JP. Gonzalez ER, et al. Resuscitation. 1998 Oct-Nov;39(1-2):33-42. doi: 10.1016/s0300-9572(98)00111-7. Resuscitation. 1998. PMID: 9918445 Review.
Amiodarone's primary mechanism is to prolong the cardiac action potential and repolarization time leading to an increased refractory period and reduced membrane excitability. ...The ARREST trial, a randomized trial comparing IV amiodarone to placebo, found a …
Amiodarone's primary mechanism is to prolong the cardiac action potential and repolarization time leading to an increased refr …
Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial.
Gelbenegger G, Jilma B, Horvath LC, Schoergenhofer C, Siller-Matula JM, Sulzgruber P, Grassmann D, Hamp T, Grafeneder J, Schnaubelt S, Holzer M, Krammel M. Gelbenegger G, et al. Resuscitation. 2024 Aug;201:110273. doi: 10.1016/j.resuscitation.2024.110273. Epub 2024 Jun 10. Resuscitation. 2024. PMID: 38866231 Free article. Clinical Trial.
METHODS: In this randomized, double-blind, placebo-controlled pilot trial, patients with OHCA and recurrent or refractory VF (at least 3 defibrillation attempts and last rhythm shockable), pretreated with epinephrine and amiodarone, were allocated to receive add-on treatme …
METHODS: In this randomized, double-blind, placebo-controlled pilot trial, patients with OHCA and recurrent or refractory VF (at least 3 def …
A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation.
Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K, Kangkagate C. Krittayaphong R, et al. J Med Assoc Thai. 2003 May;86 Suppl 1:S8-16. J Med Assoc Thai. 2003. PMID: 12866763 Clinical Trial.
The authors randomized 30 patients with chronic atrial fibrillation refractory to medication into amiodarone and radiofrequency ablation. The primary objective of this study was to compare the efficacy of amiodarone and radiofrequency ablation in the maintenance of …
The authors randomized 30 patients with chronic atrial fibrillation refractory to medication into amiodarone and radiofrequency ablat …
Clinical efficacy and safety of intravenous Amiodarone in infants and children.
Figa FH, Gow RM, Hamilton RM, Freedom RM. Figa FH, et al. Am J Cardiol. 1994 Sep 15;74(6):573-7. doi: 10.1016/0002-9149(94)90746-3. Am J Cardiol. 1994. PMID: 8074040 Clinical Trial.
The mean loading dose was 5 mg/kg infused over 1 hour, with a starting maintenance dose of 5 micrograms/kg/min. In 18 treatment episodes, amiodarone was used alone or in combination with digoxin. Thirteen patients received amiodarone combined with other antiarrhythm …
The mean loading dose was 5 mg/kg infused over 1 hour, with a starting maintenance dose of 5 micrograms/kg/min. In 18 treatment episodes, …
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial.
Lumer GB, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagné P, Nattel S. Lumer GB, et al. Eur Heart J. 2002 Jul;23(13):1050-6. doi: 10.1053/euhj.2001.2986. Eur Heart J. 2002. PMID: 12093058 Clinical Trial.
RESULTS: Patients in the amiodarone group had fewer electrical cardioversions (65 vs 109 for patients in the sotalol/propafenone group, P<0.0001), and pacemaker insertions (4 vs 11, P=0.07). The average amiodarone patient spent fewer days in hospital (0.47 vs 0.9 …
RESULTS: Patients in the amiodarone group had fewer electrical cardioversions (65 vs 109 for patients in the sotalol/propafenone grou …
Interaction between amiodarone and lidocaine.
Ha HR, Candinas R, Stieger B, Meyer UA, Follath F. Ha HR, et al. J Cardiovasc Pharmacol. 1996 Oct;28(4):533-9. doi: 10.1097/00005344-199610000-00009. J Cardiovasc Pharmacol. 1996. PMID: 8891878 Clinical Trial.
Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine N-monodesethylase activity in the same manner (Ki = 47 microM). ...The pharmacokinetic parameters during phase II were the same as those du …
Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine …
Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic.
Sanoski CA, Schoen MD, Gonzalez RC, Avitall B, Bauman JL. Sanoski CA, et al. Pharmacotherapy. 1998 Nov-Dec;18(6 Pt 2):146S-151S. Pharmacotherapy. 1998. PMID: 9855347 Clinical Trial.
OBJECTIVES: To review the rationale and development of a multidisciplinary amiodarone clinic, and document the clinical outcomes resulting from its implementation. ...The dose of amiodarone was adjusted in 29 (48.4%) patients. CONCLUSION: Many patients receiving …
OBJECTIVES: To review the rationale and development of a multidisciplinary amiodarone clinic, and document the clinical outcomes resu …
Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial.
Eskes SA, Endert E, Fliers E, Geskus RB, Dullaart RP, Links TP, Wiersinga WM. Eskes SA, et al. J Clin Endocrinol Metab. 2012 Feb;97(2):499-506. doi: 10.1210/jc.2011-2390. Epub 2011 Nov 30. J Clin Endocrinol Metab. 2012. PMID: 22130792 Clinical Trial.
CONTEXT: Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone. When prednisone fails to restore euthyroidism, possibly due to mixed cases of AIT type 1 and 2, perchlorate (ClO(4)) might b …
CONTEXT: Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue …
922 results